Pliant Therapeutics Inc（PLRX）のニュースとイベントPLRXPliant Therapeutics Inc

Pliant Therapeutics Initiates FORTIFY Clinical Trial

Pliant Therapeutics announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with pembrolizumab, in patients with immune checkpoint inhibitor -refractory advanced or metastatic solid tumors. PLN-101095 is an oral, small molecule, dual selective inhibitor of the integrins alphavbeta8 and alphavbeta1.

Pliant Therapeutics Updates PLN-101095 Clinical Data

Pliant Therapeutics announced the presentation of updated data from its Phase 1 trial of PLN-101095, in combination with pembrolizumab, in patients with immune checkpoint inhibitor-refractory advanced or metastatic solid tumors. The oral presentation was made at the Clinical Trials Mini Symposium of the American Association for Cancer Research (AACR) 2026 Annual Meeting. All responding patients showed large increases in plasma interferon gamma after a 14-day run-in period of monotherapy with PLN-101095. At Week 10, all responders maintained more than a 2-fold increase in IFN-gamma. No non-responders showed meaningful increases in IFN- gamma. In addition to IFN- gamma increases, all responding patients showed elevated plasma PD-L1 levels, known to be induced by increased IFN-gamma and a predictor of an improved ICI response. As increases in IFN-gamma have the potential to serve as a biomarker of TGF-beta inhibition and an early indicator of PLN-101095 anti-tumor activity. Pliant anticipates further study of this biomarker as part of the expansion cohorts in the Phase 1b trial. PLN-101095 was generally well tolerated across all doses evaluated with few discontinuations due to adverse events. Rash was the most common treatment-related adverse event, all Grade 1 or 2, and the majority of events occurred within the first 2 days of the initial pembrolizumab dose. One Grade 3 TRAE was observed.